About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

President Biden and Sen. Bernie Sanders warned the drugmaker against "ripping off the American people."Shares of Novo Nordisk (NVO -2.00%) were slipping 1.7% lower as of 10:57 a.m. ET on Tuesday, after falling as much as 4.4% earlier in the day. The decline came after USA Today published an opinion piece in which President Joe Biden and independent Senator Bernie Sanders of Vermont called for Novo Nordisk and Eli Lilly to reduce the prices for their diabetes and obesity drugs.In the USA Today article, Biden ...

DMPAnalyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is complex and thorny. Moreover, it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators. This article begins a series of ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Wegovy was just approved in China.Novo Nordisk (NVO -1.21%) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1) medicines. The Danish drugmaker develops Ozempic, Rybelsus, Saxenda, and Wegovy.While Ozempic is approved by the Food and Drug Administration (FDA) to treat diabetes patients, its sibling medicine Wegovy is prescribed for obesity care. Just this week, Novo Nordisk received some very good news regarding Wegovy. Let's dig i ...

In the latest market close, Novo Nordisk (NVO) reached $144.49, with a +0.57% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.09% for the day. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.3%.Prior to today's trading, shares of the drugmaker had gained 8.28% over the past month. This has outpaced the Medical sector's gain of 1.69% and the S&P 500's gain of 3.38% in that time.Market participants will be closely following the f ...

Novo Nordisk (NVO) lost 2.2% on Jun 26 after the company announced the failure of a late-stage study evaluating ocedurenone to treat patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). Consequently, the company said that it will recognize an impairment loss of around DKK 5.7 billion related to the intangible assets in the second quarter of 2024.Such recognition is expected to negatively impact operating profit growth by around 6 percentage points at the constant exchange rate ...

Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024. Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease ...

Novo Nordisk is investing $4.1 billion to expand its U.S. manufacturing capacity to address the growing demand for its highly sought-after weight-loss-related drugs.  The Danish pharmaceutical manufacturer will also boost its current production investment this year to $6.8 billion, up significantly from $3.9 billion in 2023.With the funds, Novo Nordisk said it plans to add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, which will essentially double t ...

Novo Nordisk (NVO) recently announced plans to make a significant investment of $4.1 billion (approximately DKK 27 billion) to construct a second fill and finishing manufacturing facility in Clayton, NC. This new facility aims to enhance the company's capacity to produce injectable treatments for patients with obesity and other chronic diseases. This expansion underscores NVO's commitment to addressing the growing global demand for its medical products.The investment represents one of the largest manufactur ...